Crinetics Pharmaceuticals, Inc. · NASDAQ:CRNX
Crinetics Pharmaceuticals — TD Cowen 46th Annual Health Care Conference 2026
9 slides from Crinetics Pharmaceuticals's conference presentation, March 2026
Slide 1: TD Cowen 46th Annual Health Care Conference
TD Cowen 46th Annual Health Care Conference March 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. (“Crinetics,” the “company,” “we,” “us,” or “our”) cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statement
Slide 3: Our Mission
Our Mission: To be the world’s leading endocrine company that consistently pioneers new therapeutics to help patients better control their disease and improve their daily lives Acromegaly Carcinoid Syndrome Congenital Adrenal Hyperplasia ACTH-Dependent Cushing’s Syndrome Tony Ellen Wendy NETs and SS
Slide 4: Transforming Endocrine Disease Treatment from Discovery to Commercialization
Transforming Endocrine Disease Treatment from Discovery to Commercialization In-House Discovery Proven Development Commercial Execution ✓ Proven drug-hunters in ✓ Demonstrated execution ✓ Building global the difficult GPCR space with 5 positive global commercial Phase 2 or 3 readouts in capabilities
Slide 5: 2025: A Breakout Year
2025: A Breakout Year Launched PALSONIFY (paltusotine) Commercial Demonstrated Early Success Towards Market Leadership Built Fully-Integrated Pharmaceutical Company Presented Positive Phase 2 Data on Atumelnant Well-Funded into Showing Potential to 2030 Infrastructure R&D Transform CAH Treatment Ini
Slide 6: PALSONIFY: Strong Commercial Fundamentals Reflect Early Success
PALSONIFY: Strong Commercial Fundamentals Reflect Early Success Patients Providers Payers Activated and Adopting with Recognizing Value Motivated Confidence Proposition >200 >125 ~50% / ~50% Enrollment Forms Unique Palsonify Reimbursed vs. Quickstart Prescribers for Newly Filled Bottles 22/22 Enroll
Slide 7: What's Next: Late-Stage Pipeline of Transformative Assets
What’s Next: Late-Stage Pipeline of Transformative Assets PRODUCT CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGISTRATIONAL APPROVED US Patients Acromegaly (US) Paltusotine 36,0001 (Oral SST2 Agonist) Acromegaly (EU) Paltusotine Carcinoid Syndrome 18,000-34,000² (Oral SST2 Agonist) Atu
Slide 8: Upcoming Milestones
Upcoming Upcoming Milestones Milestones Potential 2026 Milestone Commercial execution of PALSONIFY in the U.S. Paltusotine Advancing paltusotine in other geographies Phase 3 CAREFNDR readout in carcinoid syndrome Phase 2/3 Equilibrium trial initiation in ADCS Additional data from ongoing Phase 1b/2a
Slide 9: Thank You
‘Crinetics Thank You
Crinetics Pharmaceuticals — TD Cowen 46th Annual Health Care Conference 2026 on 6ix